Automated World Health
Local Coverage Determination (LCD) for Vinorelbine Tartrate (Navelbine®) (L29306)
Contractor Information
Contractor Name
First Coast Service Options, Inc. opens in new window
Contractor Number 09102
Contractor Type MAC - Part B
LCD Information
Document Information
LCD ID Number L29306
LCD Title
Vinorelbine Tartrate (Navelbine®)
Contractor's Determination Number J9390
Primary Geographic Jurisdiction opens in new window Florida
Oversight Region Region IV
AMA CPT/ADA CDT Copyright Statement
CPT only copyright 2002-2011 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association.
Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2010 are trademarks of the American Dental Association.
Original Determination Effective Date
For services performed on or after 02/02/2009 Original Determination Ending Date
Revision Effective Date
Revision Ending Date
CMS National Coverage Policy
Language quoted from CMS National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals are italicized throughout the Local Coverage Determination (LCD). NCDs and coverage provisions in interpretive manuals are not subject to the LCD Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See §1869(f)(1)(A)(i) of the Social Security Act.
Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources: CMS Manual System, Pub. 100-2, Medicare Benefit Policy, Chapter 15, Section 50
CMS Manual System, Pub. 100-4, Medicare Claims Processing Manual, Chapter 17, Section 40
CMS Manual System, Pub. 100-8, Medicare Program Integrity, Chapter 13, Section 13.1.3
Indications and Limitations of Coverage and/or Medical Necessity Vinorelbine tartrate (Navelbine®)–J9390
Vinorelbine tartrate (Navelbine) is a semi-synthetic derivative of vinblastine. It belongs to a group of chemicals called vinca alkaloids. The chemical structure and biological action or vinorelbine is similar to vinblastine and vincristine. Vinorelbine prevents the formation of microtubules in cells. One of the roles in microtubules is to aid in the replication of cells. By disrupting this function vinorelbine inhibits cell replication, including the replication of cancer cells.
Vinorelbine is FDA approved for use as a single agent or in combination with cisplatin for the first-line treatment
of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, vinorelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, vinorelbine is indicated in combination with cisplatin.
Medicare will consider Vinorelbine medically reasonable and necessary when provided for its FDA approved uses, as well as for the treatment of the following off-labeled indications:
• Cervical carcinoma
• Epithelial ovarian carcinoma
• Metastatic breast carcinoma in patients who did not respond to standard first-line chemotherapy for metastatic disease. It is also indicated for patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.
• Hormone refractory prostate carcinoma
• Primary peritoneal carcinoma
• Fallopian tube carcinoma
Coding Information
Bill Type Codes:
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.
999x Not Applicable
Revenue Codes:
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.
99999 Not Applicable
CPT/HCPCS Codes
J9390 INJECTION, VINORELBINE TARTRATE, 10 MG
ICD-9 Codes that Support Medical Necessity
158.8 MALIGNANT NEOPLASM OF SPECIFIED PARTS OF PERITONEUM
158.9 MALIGNANT NEOPLASM OF PERITONEUM UNSPECIFIED
162.0 - 162.9 opens in new window
174.0 - 174.9 opens in new window
175.0 - 175.9 opens in new window
180.0 - 180.9 opens in new window
183.0 - 183.9 opens in new window
MALIGNANT NEOPLASM OF TRACHEA - MALIGNANT NEOPLASM OF BRONCHUS AND LUNG UNSPECIFIED
MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF FEMALE BREAST - MALIGNANT NEOPLASM OF BREAST (FEMALE) UNSPECIFIED SITE
MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF MALE BREAST - MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED SITES OF MALE BREAST
MALIGNANT NEOPLASM OF ENDOCERVIX - MALIGNANT NEOPLASM OF CERVIX UTERI UNSPECIFIED SITE
MALIGNANT NEOPLASM OF OVARY - MALIGNANT NEOPLASM OF UTERINE ADNEXA UNSPECIFIED SITE
185 MALIGNANT NEOPLASM OF PROSTATE
197.6 SECONDARY MALIGNANT NEOPLASM OF RETROPERITONEUM AND PERITONEUM
Diagnoses that Support Medical Necessity
See ICD-9 Codes that Support Medical Necessity
ICD-9 Codes that DO NOT Support Medical Necessity
All other diagnosis codes not listed as covered in the “ICD-9 Codes that Support Medical Necessity” section of this LCD.
XX000 Not Applicable
ICD-9 Codes that DO NOT Support Medical Necessity Asterisk Explanation
Diagnoses that DO NOT Support Medical Necessity
All other diagnoses not listed as covered in the “ICD-9 Codes that Support Medical Necessity” section of this LCD. Back to Top
General Information
Documentations Requirements
Medical record documentation maintained by the ordering/referring physician must substantiate the medical need for the use of these chemotherapy drugs by clearly indicating the condition for which these drugs are being used. This might include the type of cancer, staging, if applicable, prior therapy and the patient’s response to that therapy. This documentation is usually found in the history and physical or in the office/progress notes.
If the provider of the service is other than the ordering/referring physician, that provider must maintain copies of the ordering/referring physician’s order for the chemotherapy drug. The physician must state the clinical indication/medical need for using the chemotherapy drug in the order.
Appendices
Utilization Guidelines is expected that these services would be performed as indicated by current medical literature and/or standards of practice. When services are performed in excess of established parameters, they may be subject to review for medical necessity.
Sources of Information and Basis for Decision
Compendia-Based Drug Bulletin. (February 2007). The Association of Community Cancer Centers. [On-Line]. Available: http://www.accc-cancer.org/.
National Comprehensive Cancer Network (2007). Non-Small Cell Lung Cancer. Clinical Practice Guidelines in Oncology – V.1.2007.
Oudard, S., Caty, A., Humblet, Y., Beauduin, M., Suc., E., Piccart, M., Rolland, F., Fumoleau, P., Bugat, R., Houyau, P., Mmonnier, A., Sun, X., Monteuquet, P., Breza, J., Novak, J., Gil, T., & Chopin, D. (2001). Phase II study of Vinorelbine in patients with androgen independent prostate cancer. Annals of Oncology, 12(6), 847-852. This study supports the use of Vinorelbine for the treatment of prostate cancer.
Sweeney, C., Monaco, F., Jung, S., Wasielewski, M., Picus, J., Anarsi, R., Dugan, W. & Einhorn, L. (2002). A phase II hoosier oncology group study of Vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Annals of Oncology, 16, 435-440. This study supports the use of Vinorelbine for the treatment of prostate cancer.
Thomson Micromedex (2007). USP DI Drug Information for the Health Care Professional. [On-Line]. Available: http://www.thomsonhc.com/home/dispatch
U.S. Food and Drug Administration, Department of Health and Human Services, CDER web site updates, April 2007.
Advisory Committee Meeting Notes This Local Coverage Determination (LCD) does not reflect the sole opinion of the contractor or Contractor Medical Director. Although the final decision rests with the contractor, this LCD was developed in cooperation with advisory groups, which includes representatives from numerous societies.
Start Date of Comment Period
End Date of Comment Period
Start Date of Notice Period 12/04/2008
Revision History Number Original
Revision History Explanation Revision Number:Original Start Date of Comment Period:N/A
Start Date of Notice Period:12/04/2008 Revised Effective Date:02/02/2009
LCR B2009-
December 2008 Bulletin
This LCD consolidates and replaces all previous policies and publications on this subject by the carrier predecessors of First Coast Service Options, Inc. (Triple S and FCSO).
For Florida (00590) this LCD (L29306) replaces LCD L25080 as the policy in notice. This document (L29306) is effective on 02/02/2009.
Reason for Change
Related Documents
This LCD has no Related Documents.
LCD Attachments
There are no attachments for this LCD.
All Versions
Updated on 11/30/2008 with effective dates 02/02/2009 - N/A Read the LCD Disclaimer opens in new window